Table 3 Variables associated with RECIST defined response to CTX
Clinical response | p valuea | |||
|---|---|---|---|---|
Variable | All cases N. | Complete and Partial response N. (%) | Stable and Progressive disease N. (%) | |
GCIG response | ||||
Complete/Partial | 16 | 9 (56.2) | 7 (43.7) | |
SD/Progression | 35 | 0 | 35 (100) | 0.0001 b |
Histotype | ||||
Serous | 45 | 7 (15.5) | 38 (84.4) | |
Other | 9 | 4 (44.4) | 5 (55.5) | 0.07 |
Pattern of recurrence | ||||
Carcinomatosis | 43 | 9 (20.9) | 34 (79.1) | |
Isolated lymph node or parenchymal disease | 11 | 2 (18.2) | 9 (81.8) | 0.69 |
Platinum sensitivity | ||||
Refractory/resistant | 20 | 3 (15.0) | 17 (85.0) | |
Sensitive | 34 | 8 (23.5) | 26 (76.5) | 0.51 |
No. previous chemotherapy lines | ||||
≤4 | 34 | 7 (20.6) | 27 (79.4) | |
>4 | 20 | 4 (20.0) | 16 (80.0) | 0.38 |